Novo Nordisk A/S
This study is being done to look at the safety and how the body takes up, breaks down and removes NNC0721-5186 in people living with overweight or obesity when compared to placebo. In the first 3 dosing groups, NNC0721-5186 will also be compared with semaglutide, a medicine already approved for weight management. Participants will either get NNC0721-5186, semaglutide, or placebo. Which treatment participants get is decided by chance.
Inclusion Criteria: 1. Female (sex at birth). 2. Age 18 to 55 years (both inclusive) at the time of signing the informed consent. 3. Body Mass Index 25.0 to 39.9 kg/m\^2 (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator. 4. Considered eligible based on the medical history, physical examination and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: 1. Known or suspected hypersensitivity to study intervention(s) or related pr…
NNC0721-5186 is administered as a single subcutaneous injection.
Semaglutide is administered as a single subcutaneous injection using a pen-injector.
Placebo is administered as a single subcutaneous injection matching NNC0721-5186.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.